PFM
RARE icon

Privium Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Privium Fund Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Sell
338,800
-26,002
-7% -$646K 2.08% 16
2026
Q1 		$7.64M Buy
364,802
+7,300
+2% +$164K 1.59% 20
2025
Q4 		$8.22M Buy
357,502
+67,698
+23% +$2.23M 1.51% 20
2025
Q3 		$8.72M Buy
289,804
+36,500
+14% +$1.09M 1.57% 14
2025
Q2 		$9.18M Buy
253,304
+3,500
+1% +$126K 1.98% 12
2025
Q1 		$9.05M Sell
249,804
-8,576
-3% -$357K 2.36% 7
2024
Q4 		$10.9M Buy
258,380
+15,868
+7% +$787K 2.46% 10
2024
Q3 		$13.5M Sell
242,512
-9,090
-4% -$463K 3.35% 8
2024
Q2 		$10.3M Buy
251,602
+36,500
+17% +$1.56M 2.63% 10
2024
Q1 		$10M Buy
215,102
+48,596
+29% +$2.29M 2.68% 10
2023
Q4 		$8.02M Buy
166,506
+51,265
+44% +$1.99M 2.23% 13
2023
Q3 		$4.11M Buy
115,241
+3,000
+3% +$119K 1.22% 25
2023
Q2 		$5.24M Buy
112,241
+1,500
+1% +$69.6K 1.51% 20
2023
Q1 		$4.44M Buy
110,741
+4,000
+4% +$172K 1.49% 22
2022
Q4 		$4.82M Buy
106,741
+24,400
+30% +$960K 1.83% 19
2022
Q3 		$3.34M Sell
82,341
-22,558
-22% -$1.16M 1.21% 29
2022
Q2 		$6.26M Sell
104,899
-7,828
-7% -$482K 2.07% 15
2022
Q1 		$8.19M Buy
112,727
+10,896
+11% +$758K 1.81% 15
2021
Q4 		$8.58M Buy
+101,831
New +$8.29M 1.7% 19

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Privium Fund Management's RARE Position: Q2 2026 in Review

Privium Fund Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 7.1% in Q2 2026, selling an estimated $646K and leaving 338,800 shares worth $11.3M. The position accounts for 2.08% of the portfolio, ranked #16.

Privium Fund Management first reported a position in RARE in Q4 2021 and has held it in 19 quarters since. The position peaked at $13.5M in Q3 2024. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Privium Fund Management held 338,800 shares of Ultragenyx Pharmaceutical worth $11.3M as of Q2 2026.
  • Privium Fund Management sold 26,002 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $646K.
  • Ultragenyx Pharmaceutical made up 2.08% of Privium Fund Management's portfolio in Q2 2026, its #16 holding.
  • Privium Fund Management first reported a position in Ultragenyx Pharmaceutical in Q4 2021 and has held it in 19 quarters since.
  • Privium Fund Management's Ultragenyx Pharmaceutical position peaked at $13.5M in Q3 2024.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.